1. Mirvetuximab soravtansine-gynx (MIRV), significantly improved progression-free survival,...
Read More
1. The median overall survival was similar between both groups, 15.2 months in atezolizumab...
Read More
1. In all patients, there was a 44% reduction in risk of colorectal cancer when using GLP-1RAs as...
Read More
1. In this cross-sectional study, having carrier status of actionable genes identified by the...
Read More
1. Median PFS and OS between the tiragolumab and control arms were similar 2. Treatment-related...
Read More
1. This retrospective cohort study tested ovarian tumors for 113 viruses and found six viruses of...
Read More
1. In this case-control study, those with tongue cancer were found to have ten-fold increases in...
Read More
Individuals with diabetes who undergo colorectal cancer (CRC) screening, specifically colonoscopy, may be able to mitigate the risk for CRC.
Read More
An evidence-based guideline to help healthcare professionals give sound advice regarding mental health to people with cancer is sorely needed.
Read More
1. The median overall survival was 12.1 months in the erdafitinib group and 7.8 months in the...
Read More
1. Overall pathologic complete response to treatment of triple-negative breast cancer with a...
Read More
1. Progression-free survival was not reached in the selpercatinib group and was 16.8 months in the...
Read More
1. For patients with unfavorable nonmetastatic prostate cancer aged above 70 years, PSA levels...
Read More
Bookmark1. A greater percentage of patients who received concurrent stereotactic radiation therapy...
Read More
Bookmark1. Progression-free survival was 6.3 months for the amivantamab–chemotherapy group, 8.3...
Read More
Bookmark1. This phase 3 randomised trial demonstrated that compared with placebo in combination...
Read More
Bookmark1. Median overall survival increased by 3.2 months in the sacituzumab govitecan group...
Read More
Bookmark1. In this cross-sectional study, cancer patients enrolled in clinical trials demonstrated...
Read MoreBookmark1. The progression-free survival was 24.8 months in the selpercatinib group vs 11.2 months in the control group (chemotherapy ± pembrolizumab), with an HR of 0.46. 2. Grade ≥3 adverse events occurred in 70% vs 57%...
Read More
Bookmark1. Median progression-free survival was 11.4 months in the amivantamab–chemotherapy group...
Read More
